DDrare: Database of Drug Development for Rare Diseases

211. 左心低形成症候群
［臨床試験数：20，薬物数：28（DrugBank：9），標的遺伝子数：5，標的パスウェイ数：13］

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03525418 (ClinicalTrials.gov)	February 21, 2018	19/2/2018	Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)	Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)	HLHS	Biological: Longeveron Mesenchymal Stem Cells	Longeveron LLC	NULL	Active, not recruiting	N/A	1 Year	All	30	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03525418
(ClinicalTrials.gov)

February 21, 2018

19/2/2018

Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)

Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)

HLHS

Biological: Longeveron Mesenchymal Stem Cells

Longeveron LLC

NULL

Active, not recruiting

N/A

1 Year

All

Phase 1;Phase 2

United States